Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jps.24375 http://scihub22266oqcxt.onion/10.1002/jps.24375 C4522399!4522399!25645375     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Pharm+Sci 2015 ; 104 (9): 2864-76 Nephropedia Template TP {{tp|p=25645375|t=2015. Synthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs to Target the Liver |pdf=|usr=}}{{25645375}} gab.com Text Synthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs to Target the Liver JO: J Pharm Sci http://www.kidney.de/pget.php?&tw=1&pmid=25645375 #FOAvip Ribavirin is used to treat hepatitis C but causes serious hemolytic anemia. The objective of the study was to develop a ribavirin prodrug to achieve liver specific drug delivery and to reduce its off-target effect in red blood cells (RBC). The approach aimed to target the human sodium taurocholate cotransporting polypeptide (NTCP), which is a bile acid transporter predominately expressed in the liver. Six prodrugs with ribavirin conjugation at C-3 or C-24 of the bile acids were synthesized. In vitro uptake studies indicated that all six prodrugs were NTCP substrates. Metabolic studies in vitro indicated that ribavirin-L-Val-GCDCA was able to release ribavirin in the mouse liver S9 fraction. Additionally, in vitro studies showed that ribavirin in RBC was reduced by 16.7 fold from prodrug compared to parent drug incubation. Moreover, almost no prodrug was present in RBC. In vivo study in mice also showed that ribavirin-L-Val-GCDCA could provide almost the same ribavirin exposure in the liver as ribavirin administration, but with about 1.8-fold less exposure of ribavirin in RBC, plasma, and kidney. Overall, the study suggested that ribavirin-L-Val-GCDCA has the potential to achieve ribavirin specific liver delivery. Twit Text FOAVip Synthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs to Target the Liver ????J Pharm Sci http://www.kidney.de/pget.php?&tw=1&pmid=25645375 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25645375 #FOAvip English Wikipedia <ref>{{Cite pmid|25645375}}</ref> Synthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs to Target the Liver #MMPMID25645375 Dong Z; Li Q; Guo D; Shu Y; Polli JE J Pharm Sci 2015[Sep]; 104 (9): 2864-76 PMID25645375show ga Ribavirin is used to treat hepatitis C but causes serious hemolytic anemia. The objective of the study was to develop a ribavirin prodrug to achieve liver specific drug delivery and to reduce its off-target effect in red blood cells (RBC). The approach aimed to target the human sodium taurocholate cotransporting polypeptide (NTCP), which is a bile acid transporter predominately expressed in the liver. Six prodrugs with ribavirin conjugation at C-3 or C-24 of the bile acids were synthesized. In vitro uptake studies indicated that all six prodrugs were NTCP substrates. Metabolic studies in vitro indicated that ribavirin-L-Val-GCDCA was able to release ribavirin in the mouse liver S9 fraction. Additionally, in vitro studies showed that ribavirin in RBC was reduced by 16.7 fold from prodrug compared to parent drug incubation. Moreover, almost no prodrug was present in RBC. In vivo study in mice also showed that ribavirin-L-Val-GCDCA could provide almost the same ribavirin exposure in the liver as ribavirin administration, but with about 1.8-fold less exposure of ribavirin in RBC, plasma, and kidney. Overall, the study suggested that ribavirin-L-Val-GCDCA has the potential to achieve ribavirin specific liver delivery. äSynthesis and Evaluation of Bile acid-ribavirin Conjugates as Prodrugs(epmc).pdf DeepDyve Pubget Overpricing